In spite of dramatic advances in the treatment of multiple myeloma over the years, it remains incurable. Identification of new drug targets is therefore necessary to improve the various drug options and therapeutic strategies. Our approach is to use the resources developed by the Human Genome Project to identify defects in a group of enzymes called kinases. These proteins are known to be responsible for some types of leukemias, skin cancers (melanoma), and numerous other cancers of the colon, breast, ovary, and lung. If defects are found in these enzymes, they can be used to develop diagnostic tests and drugs to treat multiple myeloma.